EQS-News: M1 Kliniken announces change in the Management Board and confirms long-term growth strategy
|
EQS-News: M1 Kliniken AG
/ Key word(s): Personnel
M1 Kliniken announces change in the Management Board and confirms long-term growth strategy Berlin, 11 June 2024 - Kilian Brenske, member of the Management Board since 2022, has asked the Supervisory Board to terminate his position on the Management Board for private reasons. The areas of national and international expansion, marketing, purchasing and sales, which he was previously responsible for together with Co-CEO Attila Strauss, will in future be managed by Attila Strauss alone. Uwe Zimdars, Chairman of the Supervisory Board of M1 Kliniken AG, comments: ‘The Supervisory Board would like to thank Kilian Brenske for his many years of service to the company, his commitment to M1 Kliniken and the consistently good and trusting cooperation. We deeply regret that Mr Brenske has decided to step down from his position for personal reasons." Attila Strauss emphasises the ambitious growth targets of M1 Kliniken: ‘We have been able to significantly increase sales and profits since 2022. In the first quarter of 2024, Group EBIT rose by 70% to EUR 6.8 million and we are also very satisfied with the performance of the second quarter of 2024 to date. Sales of between EUR 80 million and EUR 90 million and EBIT of between EUR 18 million and EUR 22 million are expected for the Beauty segment in the current financial year. By 2029, the company plans to achieve sales of EUR 200 to 300 million in the Beauty segment with an EBIT margin of at least 20%.“
M1 Kliniken AG is the leading fully integrated provider of aesthetic medical healthcare services in Europe. The Group offers products and services of the highest quality standards in the aesthetic and surgical fields. Beauty medical treatments are currently offered at 61 specialist centres under the "M1 Med Beauty" brand. With six operating rooms and 35 beds, the “M1 Schlossklinik” for Plastic and Aesthetic Surgery in Berlin is one of the largest and most modern facilities of its kind in Europe. M1 Kliniken has been driving forward its internationalisation since the end of 2018 and is currently represented in ten countries.
Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
11.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1922875 |
| End of News | EQS News Service |
|
|
1922875 11.06.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 65,21 | 77,27 | 159,59 | 314,61 | 285,29 | 316,32 | 350,00 | |
| EBITDA1,2 | 7,17 | 11,33 | 8,89 | 17,82 | 15,41 | 21,01 | 31,00 | |
| EBITDA-Margin3 | 11,00 | 14,66 | 5,57 | 5,66 | 5,40 | 6,64 | 8,86 | |
| EBIT1,4 | 6,46 | 7,93 | 4,41 | 12,13 | 9,35 | 15,70 | 26,70 | |
| EBIT-Margin5 | 9,91 | 10,26 | 2,76 | 3,86 | 3,28 | 4,96 | 7,63 | |
| Net Profit (Loss)1 | 6,61 | 9,73 | 7,43 | 10,88 | 7,07 | 11,67 | 16,20 | |
| Net-Margin6 | 10,14 | 12,59 | 4,66 | 3,46 | 2,48 | 3,69 | 4,63 | |
| Cashflow1,7 | 2,86 | -5,37 | 9,54 | 15,68 | 20,77 | 7,81 | 11,00 | |
| Earnings per share8 | 0,39 | 0,56 | 0,37 | 0,45 | 0,22 | 0,54 | 0,78 | |
| Dividend per share8 | 0,30 | 0,00 | 0,00 | 0,00 | 0,00 | 0,50 | 0,30 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: wetreu NTRG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| M1 Kliniken | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0STSQ | DE000A0STSQ8 | AG | 309,38 Mio € | 14.09.2015 | Kaufen | 9F4MCHV9+6R |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 16,94 | 26,66 | 0,64 | 36,63 | 3,11 | 39,62 | 0,98 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,50 | 0,30 | 1,90% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 17.07.2024 | 06.06.2024 | 03.09.2024 | 19.11.2024 | 23.05.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -4,98% | -3,55% | +40,63% | +46,51% | +235,11% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
